Compare Expensify Inc (EXFY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs GeneDx Holdings Corp — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 9.7× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and GeneDx Holdings Corp for 19 Days on average.
| EXFY | WGS | |
|---|---|---|
Market Cap | $208.82M | $2.02B |
Volume | 456,102 | 734,640 |
Sector | Technology | Health |
52-Week High | $2.72 | $167.51 |
52-Week Low | $0.75 | $34.51 |
Typical Hold Time | 41 Days | 19 Days |
Enterprise Value | $148.44M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.40, up 5.73% today, showing technical bullish momentum. The company reported mixed quarterly results with recent beats but remains unprofitable with negative margins. Recent business developments include strategic AI integrations and European expansion of its corporate card program, signaling growth initiatives. Analyst sentiment is cautiously optimistic with a 50% buy rating and $13.75 consensus target, though fundamentals show continued losses.
The outlook remains speculative given persistent negative profitability despite revenue stabilization. Investment opportunity hinges on successful execution of AI integrations and international expansion driving future profitability. Key risks include competitive pressure in expense management software and the challenge of achieving sustainable positive earnings amid ongoing operational losses.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
